Literature DB >> 11483837

Infection with Sin Nombre hantavirus: clinical presentation and outcome in children and adolescents.

M M Ramos1, G D Overturf, M R Crowley, R B Rosenberg, B Hjelle.   

Abstract

OBJECTIVE: Sin Nombre hantavirus (SNV) is the leading causative agent of hantavirus cardiopulmonary syndrome (HCPS) in the United States and Canada. Relatively few cases of HCPS have involved children. This report describes the clinical characteristics of a series of pediatric cases of SNV infection in the United States and Canada from 1993 through March 2000.
METHODS: We analyzed clinical and laboratory data on 13 patients who were </=16 years old with SNV infection from 1993 through March 2000 identified from a database at the University of New Mexico.
RESULTS: The patients ranged from 10 to 16 years of age, with a median of 14. Fifty-four percent were female. Fifty-four percent were Native American. The most common prodromal symptoms were fever, headache, and cough or dyspnea (100%); nausea or vomiting (90%); and myalgia (80%). The most common physical findings at admission were tachypnea (67%) and fever (56%); hypotension was seen in 33% of patients. On admission, all patients manifested thrombocytopenia (median platelet count: 67 000/mm(3)) and elevated lactate dehydrogenase (median level: 1243 IU/L), and >85% of patients had elevated levels of serum aspartate aminotransferase, alanine aminotransferase, and hypoalbuminemia. Leukocytosis and hemoconcentration were seen in less than one third of patients at admission. HCPS developed in 12 of the 13 patients (92%), and 4 of those 12 died (33% case-fatality ratio). The majority of HCPS patients (8 of 12 [67%]) were critically ill and required mechanical ventilation. Extracorporeal membrane oxygenation was used in 2 patients, 1 of whom survived. An elevated prothrombin time (>/=14 seconds) at admission was predictive of mortality.
CONCLUSIONS: Infection with SNV in children and adolescents causes HCPS with a clinical course and mortality rate similar to that described in adults. We believe that early recognition of HCPS in children and adolescents and appropriate referral to tertiary care centers that are experienced with HCPS are important in reducing mortality.

Entities:  

Mesh:

Year:  2001        PMID: 11483837     DOI: 10.1542/peds.108.2.e27

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  5 in total

Review 1.  Hantaviruses.

Authors:  Mohammed A Mir
Journal:  Clin Lab Med       Date:  2010-03       Impact factor: 1.935

2.  Hantavirus pulmonary syndrome, United States, 1993-2009.

Authors:  Adam MacNeil; Thomas G Ksiazek; Pierre E Rollin
Journal:  Emerg Infect Dis       Date:  2011-07       Impact factor: 6.883

3.  Elevated cytokines, thrombin and PAI-1 in severe HCPS patients due to Sin Nombre virus.

Authors:  Virginie Bondu; Ron Schrader; Mary Ann Gawinowicz; Paul McGuire; Daniel A Lawrence; Brian Hjelle; Tione Buranda
Journal:  Viruses       Date:  2015-02-10       Impact factor: 5.048

4.  Hantavirus pulmonary syndrome in children: case report and case series from an endemic area of Brazil.

Authors:  Ana Cláudia Pereira Terças-Trettel; Alba Valéria Gomes de Melo; Sandra Mara Fernandes Bonilha; Josdemar Muniz de Moraes; Renata Carvalho de Oliveira; Alexandro Guterres; Jorlan Fernandes; Marina Atanaka; Mariano Martinez Espinosa; Luciana Sampaio; Sumako Kinoshieta Ueda; Elba Regina Sampaio de Lemos
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2019-12-20       Impact factor: 1.846

5.  Serological Evidence of Human Orthohantavirus Infections in Barbados, 2008 to 2016.

Authors:  Kirk Osmond Douglas; Thelma Alafia Samuels; Rommel Iheozor-Ejiofor; Olli Vapalahti; Tarja Sironen; Marquita Gittens-St Hilaire
Journal:  Pathogens       Date:  2021-05-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.